血清维生素D水平与代谢功能障碍相关的脂肪性肝病之间的关联:基于NHANES 2021-2023的横截面研究
Shuo Zhou1,2, Xiao You2, Dengyong Zhang2
1School of Medicine, Nankai University, Tianjin, China.
Annals of medicine and surgery (2012)
|December 11, 2025
概括
较高的维生素D水平与较低的代谢功能障碍相关脂肪性肝病 (MASLD) 风险有关. 这表明维生素D可能是管理MASLD的可修改因素.
科学领域:
- 内分泌学 在内分泌学.
- 肝病学 肝病学是一种肝病学.
- 营养科学 营养科学
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个显著且日益严重的全球健康问题.
- 新兴研究表明,维生素D可能与MASLD的发展有关.
研究的目的:
- 研究血清维生素D水平与患MASLD的风险之间的关系.
- 为此分析,利用国家健康和营养检查调查 (NHANES) 的数据.
主要方法:
- 分析了3249名美国成年人的数据 (NHANES 2021-2023周期).
- 基于控制减弱参数 (CAP) 值≥248 dB/m的MASLD诊断.
- 使用多变量后勤回归,接收器操作特征 (ROC) 分析,校准曲线,决策曲线分析 (DCA) 和调解分析.
主要成果:
- 在MASLD组中,维生素D水平的中位数较低 (77.35比82.10nmol/L),在最低维生素D四分位数中患病率更高.
- 在维生素D水平和MASLD患病率之间发现了反向关联 (或0.965每10nmol/L增加,P=0.005).
- 完全调整后的模型显示出强大的预测性能 (AUC 0.825) 和通过DCA的临床实用性,调解分析确定BMI,HDL和HbA1c作为关键调解因素.
结论:
- 维生素D水平升高与MASLD的几率降低有关.
- 维生素D可以作为可修改的风险因素和MASLD的潜在治疗点.
- 进一步研究维生素D在MASLD病原和管理中的作用是有必要的.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Role of Skin in Vitamin D Synthesis
7.5K
The skin plays a crucial role in the synthesis of vitamin D, a vital nutrient for various physiological processes in the body. Vitamin D is unique because it can be synthesized in the skin through a series of chemical reactions triggered by exposure to ultraviolet B (UVB) radiation from sunlight.
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
7.5K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200
Connective Tissue Cell Types
4.0K
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
4.0K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
192
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
192
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
236
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
236


